#Minneapolis #Bio-Techne #RD Systems #Designer Protein

Bio-Techne Introduces Enhanced Protein Solutions for Cell Therapy

Bio-Techne Corporation (NASDAQ: TECH), a prominent player in the life sciences sector, has recently announced the expansion of its RD Systems™ AI-Engineered Designer Protein portfolio. This new launch aims to tackle the challenges of reproducibility and performance that researchers face in advanced cell culture and cell therapy workflows.

The RD Systems AI-Engineered Designer Protein platform is a result of cutting-edge engineering practices designed to create novel protein-based solutions. These latest developments focus on improving the stability and activity of crucial reagents used in cell culturing processes. With advancements in heat stability, solubility, and activity of proteins, researchers can now expect consistent outcomes while scaling up their workflows from initial research phases to therapeutic development.

The recent enhancements come at a crucial time as the field of regenerative medicine transitions into the clinical and commercial phases. Any variability in cell signaling inputs can significantly affect therapeutic outcomes, making reliability in these processes paramount. This new line of proteins not only supports basic research but also aids in large-scale manufacturing processes.

Bio-Techne's breakthrough innovations include hyperactive cytokines and heat-stable growth factors specifically tailored for diverse applications such as stem cell culture and organoid development. These proteins have shown promise in overcoming significant roadblocks encountered in scaling up cell therapy.

A notable expert in the field, Dr. Branden Moriarity from the University of Minnesota, emphasized the importance of these advancements, stating, "Many patient-derived Tumor-Infiltrating Lymphocytes (TIL) samples often fail to expand properly. The IL-2 Heat Stable Agonist Protein has demonstrated potential in not only enhancing TIL proliferation but also in streamlining the operational facets of TIL therapies, which can ultimately lower overall costs."

The newly launched proteins include:

• - FGF-4 Heat Stable: Facilitates maintenance of pluripotent stem cells and aids in embryonic development protocols.
• - FGF-7 Heat Stable: Key in epithelial regeneration and suitable for the demands of advanced 3D culture systems and organoids.
• - FGF-8b Heat Stable: Optimally designed for applications where accurate morphogenic signaling is essential in research involving developmental biology.
• - IL-3 Heat Stable: Vital for expanding hematopoietic stem and progenitor cells, crucial for various lineage commitment stages requiring cytokine stability.
• - IL-15 Hyperactive: This protein enhances the proliferation of NK and T cells, crucial for both cell therapy and immunotherapy research.

According to Will Geist, President of Bio-Techne's Protein Science Segment,